Efgartigimod is a newly approved FcRn antagonist for the treatment of myasthenia gravis, which rapidly cleans IgG antibodies in the body, but there is still a lack of guidance on the use of efgartigimod in patients with renal insufficiency. This evidence concerns the gene FCGRT and Renal insufficiency.